In vitro dissolution models for the prediction of in vivo performance of an oral mesoporous silica formulation

Journal of Controlled Release

Volumn 250, Issue , 2017, Pages 86-95

  McCarthy, Carol A ^a   Faisal, Waleed ^a,b   O'Shea, Joseph P ^a   Murphy, Colm ^a   Ahern, Robert J ^a   Ryan, Katie B ^a   Griffin, Brendan T ^a   Crean, Abina M ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b Minia University   (Egypt)

Author keywords

Dissolution; Fenofibrate; Hydrodynamics; in vitro in vivo relationship (IVIVR); Mesoporous silica; Supersaturation; Transfer model

Indexed keywords

BIOCHEMISTRY; COMPUTER SOFTWARE; DRUG PRODUCTS; EQUIPMENT; FLUID DYNAMICS; FORECASTING; HYDRODYNAMICS; MESOPOROUS MATERIALS; SILICA; SUPERSATURATION;

FENOFIBRATE; FORMULATION DEVELOPMENT; IN-VITRO DISSOLUTION; IN-VIVO; MESOPOROUS SILICA; MODELLING AND SIMULATIONS; ORAL BIOAVAILABILITIES; TRANSFER MODELS;

DISSOLUTION;

FENOFIBRATE; MESOPOROUS SILICA NANOPARTICLE; DRUG CARRIER; SILICON DIOXIDE;

ANIMAL EXPERIMENT; ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; DISSOLUTION; DRUG BIOAVAILABILITY; DRUG RELEASE; DRUG SOLUBILITY; GASTROINTESTINAL TRANSIT; HYDRODYNAMICS; IN VITRO STUDY; IN VIVO STUDY; NANOPHARMACEUTICS; NONHUMAN; PORCINE MODEL; PRIORITY JOURNAL; ANIMAL; BIOAVAILABILITY; BIOLOGICAL MODEL; CHEMISTRY; COMPUTER SIMULATION; FEMALE; HUMAN; MEDICINAL CHEMISTRY; PIG; POROSITY; SOLUBILITY;

ANIMALS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; COMPUTER SIMULATION; DRUG CARRIERS; DRUG LIBERATION; FEMALE; FENOFIBRATE; HUMANS; HYDRODYNAMICS; MODELS, BIOLOGICAL; POROSITY; SILICON DIOXIDE; SOLUBILITY; SWINE;

EID: 85013230977     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2016.12.043     Document Type: Article

References (58)

1. [1] Lipinski, C.A., Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 44 (2000), 235–249.
2. [2] Pouton, C.W., Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur. J. Pharm. Sci. 29 (2006), 278–287.
3. [3] McCarthy, C.A., Ahern, R.J., Dontireddy, R., Ryan, K.B., Crean, A.M., Mesoporous silica formulation strategies for drug dissolution enhancement: a review. Expert Opin. Drug Deliv. 13 (2016), 93–108.
4. [4] Van Speybroeck, M., Barillaro, V., Thi, T.D., Mellaerts, R., Martens, J., Van Humbeeck, J., Vermant, J., Annaert, P., Van den Mooter, G., Augustijns, P., Ordered mesoporous silica material SBA-15: a broad-spectrum formulation platform for poorly soluble drugs. J. Pharm. Sci. 98 (2009), 2648–2658.
5. [5] Ahern, R.J., Hanrahan, J.P., Tobin, J.M., Ryan, K.B., Crean, A.M., Comparison of fenofibrate–mesoporous silica drug-loading processes for enhanced drug delivery. Eur. J. Pharm. Sci. 50 (2013), 400–409.
6. [6] Waters, L.J., Hussain, T., Parkes, G., Hanrahan, J.P., Tobin, J.M., Inclusion of fenofibrate in a series of mesoporous silicas using microwave irradiation. Eur. J. Pharm. Biopharm. 85 (2013), 936–941.
7. [7] Shen, S.C., Ng, W.K., Chia, L., Dong, Y.C., Tan, R.B., Stabilized amorphous state of ibuprofen by co-spray drying with mesoporous SBA-15 to enhance dissolution properties. J. Pharm. Sci. 99 (2010), 1997–2007.
8. [8] Charnay, C., Bégu, S., Tourné-Péteilh, C., Nicole, L., Lerner, D.A., Devoisselle, J.M., Inclusion of ibuprofen in mesoporous templated silica: drug loading and release property. Eur. J. Pharm. Biopharm. 57 (2004), 533–540.
9. [9] Van Speybroeck, M., Mellaerts, R., Mols, R., Thi, T.D., Martens, J.A., Van Humbeeck, J., Annaert, P., Van den Mooter, G., Augustijns, P., Enhanced absorption of the poorly soluble drug fenofibrate by tuning its release rate from ordered mesoporous silica. Eur. J. Pharm. Sci. 41 (2010), 623–630.
10. [10] Van Speybroeck, M., Mols, R., Mellaerts, R., Thi, T.D., Martens, J.A., Humbeeck, J.V., Annaert, P., Mooter, G.V.D., Augustijns, P., Combined use of ordered mesoporous silica and precipitation inhibitors for improved oral absorption of the poorly soluble weak base itraconazole. Eur. J. Pharm. Biopharm. 75 (2010), 354–365.
11. [11] Kiekens, F., Eelen, S., Verheyden, L., Daems, T., Martens, J., Van Den Mooter, G., Use of ordered mesoporous silica to enhance the oral bioavailability of ezetimibe in dogs. J. Pharm. Sci. 101 (2012), 1136–1144.
12. [12] Cao, X., Deng, W., Fu, M., Zhu, Y., Liu, H., Wang, L., Zeng, J., Wei, Y., Xu, X., Yu, J., Seventy-two-hour release formulation of the poorly soluble drug silybin based on porous silica nanoparticles: in vitro release kinetics and in vitro/in vivo correlations in beagle dogs. Eur. J. Pharm. Sci. 48 (2013), 64–71.
13. [13] Bukara, K., Schueller, L., Rosier, J., Daems, T., Verheyden, L., Eelen, S., Martens, J.A., Van den Mooter, G., Bugarski, B., Kiekens, F., In vivo performance of fenofibrate formulated with ordered mesoporous silica versus 2-marketed formulations: a comparative bioavailability study in beagle dogs. J. Pharm. Sci. 105 (2016), 2381–2385.
14. 2) processing conditions on drug loading and physicochemical properties. Int. J. Pharm. 439 (2012), 92–99.
15. [15] Kinnari, P., Mäkilä, E., Heikkilä, T., Salonen, J., Hirvonen, J., Santos, H.A., Comparison of mesoporous silicon and non-ordered mesoporous silica materials as drug carriers for itraconazole. Int. J. Pharm. 414 (2011), 148–156.
16. [16] Kumar, D., Sailaja Chirravuri, S.V., Shastri, N.R., Impact of surface area of silica particles on dissolution rate and oral bioavailability of poorly water soluble drugs: a case study with aceclofenac. Int. J. Pharm. 461 (2014), 459–468.
17. [17] Guo, Z., Liu, X.-M., Ma, L., Li, J., Zhang, H., Gao, Y.-P., Yuan, Y., Effects of particle morphology, pore size and surface coating of mesoporous silica on Naproxen dissolution rate enhancement. Colloids Surf. B Biointerfaces 101 (2013), 228–235.
18. [18] Yoncheva, K., Popova, M., Szegedi, A., Mihaly, J., Tzankov, B., Lambov, N., Konstantinov, S., Tzankova, V., Pessina, F., Valoti, M., Functionalized mesoporous silica nanoparticles for oral delivery of budesonide. J. Solid State Chem. 211 (2014), 154–161.
19. [19] Kostewicz, E.S., Abrahamsson, B., Brewster, M., Brouwers, J., Butler, J., Carlert, S., Dickinson, P.A., Dressman, J., Holm, R., Klein, S., Mann, J., McAllister, M., Minekus, M., Muenster, U., Müllertz, A., Verwei, M., Vertzoni, M., Weitschies, W., Augustijns, P., In vitro models for the prediction of in vivo performance of oral dosage forms. Eur. J. Pharm. Sci. 57 (2014), 342–366.
20. [20] Augustijns, P., Brewster, M.E., Supersaturating drug delivery systems: fast is not necessarily good enough. J. Pharm. Sci. 101 (2012), 7–9.
21. [21] Jantratid, E., Janssen, N., Reppas, C., Dressman, J.B., Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update. Pharm. Res. 25 (2008), 1663–1676.
22. [22] Perng, C.-Y., Kearney, A.S., Palepu, N.R., Smith, B.R., Azzarano, L.M., Assessment of oral bioavailability enhancing approaches for SB-247083 using flow-through cell dissolution testing as one of the screens. Int. J. Pharm. 250 (2003), 147–156.
23. [23] Sunesen, V.H., Pedersen, B.L., Kristensen, H.G., Müllertz, A., In vivo in vitro correlations for a poorly soluble drug, danazol, using the flow-through dissolution method with biorelevant dissolution media. Eur. J. Pharm. Sci. 24 (2005), 305–313.
24. [24] Okumu, A., DiMaso, M., Löbenberg, R., Dynamic dissolution testing to establish in vitro/in vivo correlations for montelukast sodium, a poorly soluble drug. Pharm. Res. 25 (2008), 2778–2785.
25. [25] Fotaki, N., Aivaliotis, A., Butler, J., Dressman, J., Fischbach, M., Hempenstall, J., Klein, S., Reppas, C., A comparative study of different release apparatus in generating in vitro–in vivo correlations for extended release formulations. Eur. J. Pharm. Biopharm. 73 (2009), 115–120.
26. [26] Vogt, M., Kunath, K., Dressman, J.B., Dissolution enhancement of fenofibrate by micronization, cogrinding and spray-drying: comparison with commercial preparations. Eur. J. Pharm. Biopharm. 68 (2008), 283–288.
27. [27] Junghanns, J.-U.A., Müller, R.H., Nanocrystal technology, drug delivery and clinical applications. Int. J. Nanomedicine, 3, 2008, 295.
28. [28] Jantratid, E., De Maio, V., Ronda, E., Mattavelli, V., Vertzoni, M., Dressman, J.B., Application of biorelevant dissolution tests to the prediction of in vivo performance of diclofenac sodium from an oral modified-release pellet dosage form. Eur. J. Pharm. Sci. 37 (2009), 434–441.
29. [29] Juenemann, D., Jantratid, E., Wagner, C., Reppas, C., Vertzoni, M., Dressman, J.B., Biorelevant in vitro dissolution testing of products containing micronized or nanosized fenofibrate with a view to predicting plasma profiles. Eur. J. Pharm. Biopharm. 77 (2011), 257–264.
30. [30] The United States Pharmacopeial Convention Inc., The United States Pharmacopeia 26, The National Formulary 21. 2003, Webcom Ltd., Canada.
31. [31] O’ Shea, J.P., Faisal, W., Ruane-O’ Hora, T., Devine, K.J., Kostewicz, E.S., O’ Driscoll, C.M., Griffin, B.T., Lipidic dispersion to reduce food dependent oral bioavailability of fenofibrate: In vitro, in vivo and in silico assessments. Eur. J. Pharm. Biopharm. 96 (2015), 207–216.
32. [32] Griffin, B.T., Kuentz, M., Vertzoni, M., Kostewicz, E.S., Fei, Y., Faisal, W., Stillhart, C., O'Driscoll, C.M., Reppas, C., Dressman, J.B., Comparison of in vitro tests at various levels of complexity for the prediction of in vivo performance of lipid-based formulations: case studies with fenofibrate. Eur. J. Pharm. Biopharm. 86 (2014), 427–437.
33. [33] Faisal, W., Ruane-O'Hora, T., O'Driscoll, C.M., Griffin, B.T., A novel lipid-based solid dispersion for enhancing oral bioavailability of Lycopene – In vivo evaluation using a pig model. Int. J. Pharm. 453 (2013), 307–314.
34. [34] U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), FDA Guidance for Industry Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/In vivo Correlations. 1997.
35. [35] Wang, S., Ordered mesoporous materials for drug delivery. Microporous and Mesoporous Mater. 117 (2009), 1–9.
36. [36] Vallet-Regí, M., Balas, F., Arcos, D., Mesoporous materials for drug delivery. Angew. Chem. Int. Ed. 46 (2007), 7548–7558.
37. [37] Xue, J.M., Shi, M., PLGA/mesoporous silica hybrid structure for controlled drug release. J. Control. Release 98 (2004), 209–217.
38. [38] Granero, G.E., Ramachandran, C., Amidon, G.L., Dissolution and solubility behavior of fenofibrate in sodium lauryl sulfate solutions. Drug Dev. Ind. Pharm. 31 (2005), 917–922.
39. [39] Jamzad, S., Fassihi, R., Role of surfactant and pH on dissolution properties of fenofibrate and glipizide—a technical note. AAPS PharmSciTech 7 (2006), E17–E22.
40. [40] Hirtz, J., The gastrointestinal absorption of drugs in man: a review of current concepts and methods of investigation. Br. J. Clin. Pharmacol. 19 (1985), 77S–83S.
41. [41] Riegelman, S., Loo, J., Rowland, M., Shortcomings in pharmacokinetic analysis by conceiving the body to exhibit properties of a single compartment. J. Pharm. Sci. 57 (1968), 117–123.
42. [42] Loo, J., Riegelman, S., New method for calculating the intrinsic absorption rate of drugs. J. Pharm. Sci. 57 (1968), 918–928.
43. [43] McCarthy, L.G., Kosiol, C., Healy, A.M., Bradley, G., Sexton, J.C., Corrigan, O.I., Simulating the hydrodynamic conditions in the united states pharmacopeia paddle dissolution apparatus. AAPS PharmSciTech 4 (2003), 83–98.
44. [44] Baxter, J.L., Kukura, J., Muzzio, F.J., Hydrodynamics-induced variability in the USP apparatus II dissolution test. Int. J. Pharm. 292 (2005), 17–28.
45. [45] D'Arcy, D.M., Corrigan, O.I., Healy, A.M., Hydrodynamic simulation (computational fluid dynamics) of asymmetrically positioned tablets in the paddle dissolution apparatus: impact on dissolution rate and variability. J. Pharm. Pharmacol. 57 (2005), 1243–1250.
46. [46] D'Arcy, D.M., Liu, B., Corrigan, O.I., Investigating the effect of solubility and density gradients on local hydrodynamics and drug dissolution in the USP 4 dissolution apparatus. Int. J. Pharm. 419 (2011), 175–185.
47. [47] Schiller, C., FrÖHlich, C.P., Giessmann, T., Siegmund, W., MÖNnikes, H., Hosten, N., Weitschies, W., Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging. Aliment. Pharmacol. Ther. 22 (2005), 971–979.
48. [48] Kostewicz, E.S., Wunderlich, M., Brauns, U., Becker, R., Bock, T., Dressman, J.B., Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine. J. Pharm. Pharmacol. 56 (2004), 43–51.
49. [49] Carlert, S., Pålsson, A., Hanisch, G., von Corswant, C., Nilsson, C., Lindfors, L., Lennernäs, H., Abrahamsson, B., Predicting intestinal precipitation—a case example for a basic BCS class II drug. Pharm. Res. 27 (2010), 2119–2130.
50. [50] Bevernage, J., Brouwers, J., Brewster, M.E., Augustijns, P., Evaluation of gastrointestinal drug supersaturation and precipitation: strategies and issues. Int. J. Pharm. 453 (2013), 25–35.
51. [51] Brouwers, J., Brewster, M.E., Augustijns, P., Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability?. J. Pharm. Sci. 98 (2009), 2549–2572.
52. [52] Hens, B., Brouwers, J., Corsetti, M., Augustijns, P., Supersaturation and Precipitation of Posaconazole upon entry in the Upper Small Intestine in Humans. J. Pharm. Sci., 2016.
53. [53] Psachoulias, D., Vertzoni, M., Goumas, K., Kalioras, V., Beato, S., Butler, J., Reppas, C., Precipitation in and supersaturation of contents of the upper small intestine after administration of two weak bases to fasted adults. Pharm. Res. 28 (2011), 3145–3158.
54. [54] Butler, J.M., Dressman, J.B., The developability classification system: application of biopharmaceutics concepts to formulation development. J. Pharm. Sci. 99 (2010), 4940–4954.
55. [55] Custodio, J.M., Wu, C.-Y., Benet, L.Z., Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv. Drug Deliv. Rev. 60 (2008), 717–733.
56. [56] Fei, Y., Kostewicz, E.S., Sheu, M.-T., Dressman, J.B., Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro–in silico–in vivo approach. Eur. J. Pharm. Biopharm. 85 (2013), 1274–1284.
57. [57] Sauron, R., Wilkins, M., Jessent, V., Dubois, A., Maillot, C., Weil, A., Absence of a food effect with a 145 mg nanoparticle fenofibrate tablet formulation. Int. J. Clin. Pharmacol. Ther., 44, 2006.
58. [58] Sjögren, E., Abrahamsson, B., Augustijns, P., Becker, D., Bolger, M.B., Brewster, M., Brouwers, J., Flanagan, T., Harwood, M., Heinen, C., Holm, R., Juretschke, H.-P., Kubbinga, M., Lindahl, A., Lukacova, V., Münster, U., Neuhoff, S., Nguyen, M.A., Peer, A.V., Reppas, C., Hodjegan, A.R., Tannergren, C., Weitschies, W., Wilson, C., Zane, P., Lennernäs, H., Langguth, P., In vivo methods for drug absorption – comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation/API/excipient characterization including food effects. Eur. J. Pharm. Sci. 57 (2014), 99–151.